Skip to main navigation Skip to search Skip to main content

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

  • Celine Callens
  • , Marc Debled
  • , Marc Delord
  • , Isabelle Turbiez-Stalain
  • , Corinne Veyret
  • , Ivan Bieche
  • , Etienne Brain

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
Original languageEnglish
Pages (from-to)383-389
JournalBreast Cancer Research and Treatment
Volume153
Issue number2
DOIs
Publication statusPublished - Sept 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Pharmacogenetics
  • SLCO1A2
  • Febrile neutropenia
  • Docetaxel
  • Breast cancer

Cite this